Abstract: Brentuximab vedotin (BV), a novel targeted antibody–drug conjugate (ADC), was first approved by the US Food and Drug Administration for the treatment of relapsed and refractory Hodgkin’s lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). BV combined with chemotherapy regimen was approved for the treatment of CD30+ peripheral T-cell lymphoma (PTCL) patients in November 2018. PTCL is a type of lymphoid system tumor with characteristics of heterogeneity, strong invasiveness, a high degree of malignancy, and poor curative effect. CD30 is differentially expressed in the PTCL subtypes, and detection of CD30 can provide guidance in diagnosis and treatment decisions. Relevant studies have shown that BV exhibits significant antitumor activity in both newly diagnosed and relapsed and refractory PTCL patients, and the efficacy in systemic anaplastic large cell lymphoma patients was significant and sustained. The clinical application of BV was generally well tolerated, and the main clinical adverse reaction was peripheral neuropathy. This article discusses the efficacy and safety of BV in the treatment of PTCL.